GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== Electrical === In electrical FFF a transverse electrical current (DC) is applied which creates an electric field. Depending on the charge of sample components, an electrophoretic drift velocity is induced, counteracted by the diffusion from Brownian motion, so the separation depends on the ratio of electrophoretic mobility and size. Application of electrical FFF has been limited and is currently rarely used. Other modifications have been developed, namely cyclical electrical FFF where a special alternating current is applied. It allows to separate according to electrophoretic mobility. Another variation is electrical asymmetrical flow FFF (EAF4), where an electrical field is applied in addition to a cross flow field. EAF4 overcomes the limitation of pure electrical FFF which has poor resolution and suffers from electrolysis products and bubbles contaminating the channel outflow and compromising the detector signals.
They distinguish these systems from other AI because they can pursue goals over many steps, call tools, and carry out tasks with relatively little human intervention. In workshops with regulators, central‑bank officials, and industry specialists, participants highlighted risks both from agentic systems built inside financial institutions and from tools offered by technology firms that can initiate or execute financial actions. In one 2025 forum, 44% of experts surveyed judged autonomous or agentic AI systems to be the most likely current source of AI‑related systemic risk in finance. In March 2025, Scale AI signed a contract with the United States Department of Defense to work with them, in collaboration with Anduril Industries and Microsoft, to develop and deploy AI agents for the purpose of assisting the military with "operational decision-making". In July 2025, Fox Business reported that the company EdgeRunner AI built an offline agent, compressed and fine-tuned on military information, with the CEO seeing more common LLMs as "heavily politicized to the left". As of that time, the company model is being used by the United States Special Operations Command in an overseas deployment. Researchers have expressed concerns that agents and the large language models they are based on could be biased towards aggressive foreign policy decisions. Research-focused agents have the risk of consensus bias and coverage bias due to collecting information available on the public internet.
The Gallery of Mineralogy, looking across the formal garden and close to the Gallery of Evolution, was constructed between 1833 and 1837 by Charles Rohault de Fleury in a neoclassical style, with two porticos of Doric columns. Directly in front is the rose garden, renewed in 1990 with 170 types of European roses, as well as a Japanese pagoda tree (Styphnolobium japonicum), planted there by Bernard de Jussieu in 1747. The gallery contains over 600,000 stones and fossils. It is particularly known for its collection of giant crystals, including colourful examples of azurite, tourmaline (rubelite), malachite and ammonite.ammonite Other displays include the jars and vestiges of the original royal apothecary of Louis XIV, and three Florentine marble marquetry tables from the palace of Cardinal Mazarin. The gallery also contains a large collection of meteorites which have been gathered from around the world. This includes a large fragment of Canyon Diablo meteorite, a piece of an asteroid which landed on Earth about 550,000 years ago and created the Meteor Crater in Arizona. It weighs 360 kg (790 lb).
This term has become very popular and commonly used in practice. But the appropriate expression is "enantioselective chromatography". Chiral chromatography has advanced to turn into the most preferred technique for the determination of enantiomeric purity as well as separation of pure enantiomers both on analytical and preparative scale. Chiral chromatographic assay is the first step in any study pertaining to enantioselective synthesis or separation. This includes the use of techniques viz. gas chromatography (GC), high performance liquid chromatography (HPLC), chiral supercritical fluid chromatography (SFC), capillary electrophoresis (CE) and thin-layer chromatography (TLC). The result of a literature survey done identifies HPLC-based chiral assays as the most dominating technology in use. An overview of various analytical methods engaged for chiral separation and analysis are listed in the table.
Sources: en.wikipedia.org
=== Role in nuclear fuel === Americium has a lower valence and lower electronegativity than plutonium, neptunium or uranium, so in most nuclear reprocessing, americium tends to fractionate with the alkaline fission products – lanthanides, strontium, caesium, barium, yttrium – rather than with lighter actinides. Americium is therefore not recycled into new nuclear fuel unless special efforts are made. In a thermal reactor, 241Am captures a neutron to become americium-242, which quickly becomes curium-242 (or, 17.3% of the time, 242Pu) via beta decay. Both 242Cm and 242Pu are much less likely to absorb a neutron, and even less likely to fission; however, 242Cm is short-lived (half-life 160 days) and almost always undergoes alpha decay to 238Pu rather than capturing another neutron. In short, most 241Am needs to absorb two neutrons before again becoming a fissile isotope, except that that becomes 242mAm (fissile) or fissions directly.
== Function == So far, ArMs can catalyze planty of chemical reactions, such as: allylic alkylation, allylic amination, aldol reaction, alcohol oxidation, C-H activation, click reaction, catechol oxidation, CO2 reduction, cyclopropanation, Diels-Alder reaction, epoxidation, epoxide ring opening, Friedel-Crafts alkylation, hydrogenation, hydroformylation, Heck reaction, Metathesis, Michael addition, nitrite reduction, NO reduction, Suzuki reaction, Si-H insertion, polymerization (atom transfer radical polymerization), atom transfer radical cyclization (ATRC), radical fluorination and proton reduction.
=== Current squad === The following players were called up for the friendly matches against Mexico, Paraguay and Peru on 26 September and 2 and 6 October 2026, respectively. Caps and goals updated as of 26 September 2026, after the match against Mexico.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.